Table 2.
Baseline characteristics according to DMT used.
| Variables* | IFN-β | GA | TNF | DMF | FYG | NTZ |
|---|---|---|---|---|---|---|
| N. of pregnancies (n of women) | 40 (37) | 5 (3) | 1 (1) | 4 (4) | 4 (4) | 27 (25) |
| Mean age, y | 37.2 ± 6.2 | 41 ± 3.5 | 39 | 35 ± 8.3 | 34.2 ± 4.9 | 35.8 ± 5.3 |
| Age at delivery, y | 29.7 ± 4.5 | 30.3 ± 2.7 | 37 | 32 ± 7 | 30 ± 5.1 | 33.4 ± 4 |
| Disease duration, y | 12.4 ± 5.5 | 15.9 ± 1.3 | 8 | 8.3 ± 4.8 | 11.8 ± 4.3 | 11.8 ± 4.6 |
| Wash out period (months) | 0.6 ± 0.7 | 2 ± 2 | 0 | 1.8 ± 0.9 | 3.2 ± 3.6 | 2.9 ± 0.6 |
| N. of relapses (n. of women) 12 months before pregnancy | 15 (15) | 1 (1) | 0 | 1 (1) | 1 (1) | 4 (3) |
| EDSS score, median (IQR) at conception | 1 (1.0–2.0) | 1.5 (1–2.0) | 1.5 (1.0–2.0) | 1.5 (1.0–2.0) | 1.5 (1.0–2.0) | 2 (1–2.5) |
| N. of pregnancies (n. of women) with MRI activity 12 months before pregnancy | 2 (2) | 0 | 0 | 0 | 2 (2) | 3 (3) |
*
Data are expressed as mean ± standard deviation when otherwise specified.
DMF, dimethylfumarate; DMTS, disease modifying therapy; EDSS, Expanded Disability Status Scale; FYG, fingolimod; GA, Glatiramer acetate; IFNs, interferons; MRI, Magnetic Resonance Imaging; n, number; NTZ, Natalizumab; TNF, teriflunomide; y, year.